CSBR
Champions Oncology Inc.
$6.75
+$0.18(+2.82%)
43
Overall
60
Value
27
Tech
--
Quality
Market Cap
$90.52M
Volume
38.38K
52W Range
$3.75 - $11.99
Target Price
$12.00
Order:
Income Statement
| Metric | Trend | Chart | 2016 Apr | 2017 Apr | 2018 Apr | 2019 Apr | 2020 Apr | 2021 Apr | 2022 Apr | 2023 Apr | 2024 Apr | 2025 Apr |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $11.2M | $15.4M | $20.2M | $27.1M | $32.1M | $41.0M | $49.1M | $53.9M | $50.2M | $56.9M | ||
| Total Revenue | $11.2M | $15.4M | $20.2M | $27.1M | $32.1M | $41.0M | $49.1M | $53.9M | $50.2M | $56.9M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | -- | $17.0M | $21.4M | $23.6M | $29.5M | $29.4M | $28.4M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $11.2M | $15.4M | $20.2M | $27.1M | $15.1M | $19.6M | $25.5M | $24.3M | $20.8M | $28.6M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-21.5M | $-22.2M | $-21.6M | $-26.8M | $34.0M | $40.7M | $24.9M | $59.1M | $57.5M | $52.4M | ||
| Research & Development | $4.2M | $4.3M | $4.4M | $4.8M | $5.9M | $7.2M | $9.4M | $11.5M | $9.5M | $6.8M | ||
| Research Expense | $4.2M | $4.3M | $4.4M | $4.8M | $5.9M | $7.2M | $9.4M | $11.5M | $9.5M | $6.8M | ||
| Selling, General & Administrative | $8.6M | $8.2M | $6.6M | $7.7M | $10.9M | $12.0M | $15.5M | $17.2M | $18.1M | $16.9M | ||
| Selling & Marketing Expenses | $3.4M | $3.3M | $2.6M | $3.1M | $4.2M | $5.5M | $6.4M | $7.0M | $7.1M | $7.5M | ||
| General & Administrative Expenses | $5.2M | $5.0M | $4.1M | $4.7M | $6.6M | $6.5M | $9.1M | $10.2M | $11.1M | $9.3M | ||
| Salaries & Wages | $-2.6M | $-2.7M | $-1.0M | $-649.0K | $56.5K | -- | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-156.0K | $-168.0K | $-360.0K | $-606.0K | $825.0K | $925.0K | $1.5M | $2.1M | $1.7M | -- | ||
| Depreciation & Amortization | $-156.0K | $-168.0K | $-360.0K | $-606.0K | $825.0K | $925.0K | $1.5M | $2.1M | -- | -- | ||
| Amortization | -- | -- | -- | -- | $423.5K | $459.0K | -- | $135.0K | $146.0K | -- | ||
| Other Operating Expenses | $8.7M | $9.7M | $10.6M | $14.3M | $-27.0K | $-3.0K | -- | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-10.3M | $-6.8M | $-1.4M | $270.0K | $-1.9M | $366.0K | $607.0K | $-5.3M | $-7.4M | $4.6M | ||
| EBITDA | $-10.2M | $-6.7M | $-1.1M | $837.0K | $-761.0K | $1.6M | $2.2M | $-3.0M | $-5.4M | $6.3M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | -- | -- | -- | -- | -- | $19.0K | -- | -- | ||
| Net Non-Operating Interest Income/Expense | -- | -- | -- | -- | -- | -- | -- | $-19.0K | $-15.0K | -- | ||
| Other Income/Expense | $38.0K | $56.0K | $89.0K | $39.0K | $42.0K | $-71.0K | $-24.0K | $818.0K | $387.0K | $220.0K | ||
| Other Special Charges | $-38.0K | $-56.0K | $-89.0K | $-39.0K | $-42.0K | $71.0K | $-24.0K | $-11.0K | $48.0K | $73.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Special Income Charges | -- | -- | -- | -- | $-335.0K | -- | -- | -- | -- | -- | ||
| Impairment of Capital Assets | -- | -- | -- | -- | $335.0K | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-10.4M | $-6.9M | $-1.4M | $231.0K | $-1.6M | $366.0K | $607.0K | $-5.2M | $-7.3M | $4.6M | ||
| Pre-Tax Income | $-10.4M | $-6.9M | $-1.4M | $231.0K | $-2.0M | $437.0K | $583.0K | $-5.3M | $-7.3M | $4.6M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $92.0K | $19.0K | $33.0K | $103.0K | $130.0K | $75.0K | $35.0K | $68.0K | $-32.0K | $-75.0K | ||
| NET INCOME | ||||||||||||
| Net Income | $-10.4M | $-6.9M | $-1.5M | $128.0K | $-2.1M | $362.0K | $548.0K | $-5.3M | $-7.3M | $4.7M | ||
| Net Income (Continuing Operations) | $-10.4M | $-6.9M | $-1.5M | $128.0K | $-2.1M | $362.0K | $548.0K | $-5.3M | $-7.3M | $4.7M | ||
| Net Income (Discontinued Operations) | $-10.4M | $-6.9M | $-1.5M | $128.0K | $-2.1M | $362.0K | $548.0K | $-5.3M | $-7.3M | $4.7M | ||
| Net Income (Common Stockholders) | $-10.4M | $-6.9M | $-1.5M | $128.0K | $-2.1M | $362.0K | $548.0K | $-5.3M | $-7.3M | $4.7M | ||
| Normalized Income | -- | -- | -- | -- | -- | $270.2K | $460.6K | -- | -- | $4.8M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-21.5M | $-22.2M | $-21.6M | $-26.8M | $51.0M | $62.1M | $48.5M | $88.7M | $86.9M | $80.8M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $8.7M | $10.7M | $11.0M | $11.3M | $11.8M | $13.1M | $13.2M | $13.5M | $13.5M | $13.7M | ||
| Average Shares Outstanding (Diluted) | $8.7M | $10.8M | $11.0M | $14.1M | $11.8M | $14.6M | $14.2M | $13.5M | $13.5M | $14.3M | ||
| Shares Outstanding | $11.2M | $11.0M | $11.0M | $11.6M | $12726.7B | $13.4M | $13.5M | $13.5M | $13.6M | $13.8M | ||
| Basic EPS | $-1.2 | -- | $-0.13 | $0.01 | $-0.17 | $0.03 | $0.04 | $-0.39 | $-0.54 | $0.34 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-0.17 | $0.03 | $0.04 | $-0.39 | $-0.54 | $0.34 | ||
| Diluted EPS | $-1.2 | $-0.64 | $-0.13 | $0.01 | $-0.17 | $0.02 | $0.04 | $-0.39 | $-0.54 | $0.33 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-0.17 | $0.02 | $0.04 | $-0.39 | $-0.54 | $0.33 | ||
| OTHER METRICS | ||||||||||||
| Gain On Sale Of P P E | -- | -- | $3.0K | -- | $52.0K | $75.0K | -- | -- | $-435.0K | $-293.0K | ||
| Other Gand A | $5.2M | $5.0M | $4.1M | $4.7M | $6.6M | $6.5M | $9.1M | $10.2M | $11.1M | $9.3M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | -- | -- | -- | -- | $807.0K | -- | -- | ||
| Rent And Landing Fees | $5.2M | $5.0M | $4.1M | $4.7M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $3.4M | $3.3M | $2.6M | $3.1M | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CSBR | $6.75 | +2.8% | 38.38K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |